Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care
暂无分享,去创建一个
M. Gent | D. Julian | J. Belch | M. Brown | Stephen Morris | J. Pittard | M. Pye | D. Betteridge | S. Long | S. Morris | Martin M. Brown
[1] V. Fuster,et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.
[2] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[3] G. Lip,et al. Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.
[4] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[5] R. Peto,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[6] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[7] R. Harbour,et al. A new system for grading recommendations in evidence based guidelines , 2001, BMJ : British Medical Journal.
[8] G. Lowe,et al. Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. , 2001, Atherosclerosis.
[9] R. Gibbons,et al. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .
[10] M. Roncaglioni. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.
[11] S. Yusuf,et al. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. , 2000, European heart journal.
[12] J. W. Schaeffer,et al. ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .
[13] M. Bertrand,et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.
[14] E. Schryver. Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin , 2000 .
[15] E. de Schryver. Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin , 2000, Cerebrovascular Diseases.
[16] H. Roskamm,et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. , 2000, Circulation.
[17] R. Ligon,et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. , 1999, Journal of the American College of Cardiology.
[18] J. Caro,et al. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. , 1999, The American journal of medicine.
[19] D. Fitzgerald,et al. Ticlopidine and clopidogrel. , 1999, Circulation.
[20] S. Pocock,et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. , 1999, The New England journal of medicine.
[21] R Brian Haynes,et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.
[22] J. Moses,et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. , 1999, Circulation.
[23] J. Meyer-Kirchrath,et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance , 1999, The Lancet.
[24] S. Pocock,et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .
[25] C. Macaya,et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.
[26] E. Fleck,et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.
[27] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[28] J. Mason,et al. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care , 1998 .
[29] M. Bell,et al. Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). , 1998, American Journal of Cardiology.
[30] Arno W. Hoes,et al. Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[31] R B D'Agostino,et al. Intermittent claudication. A risk profile from The Framingham Heart Study. , 1997, Circulation.
[32] Zheng-Ming Chen,et al. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.
[33] Peter Sandercock,et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.
[34] S. Shapiro,et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product , 1996, The Lancet.
[35] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[36] H. Diener,et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.
[37] M. Hadamitzky,et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.
[38] J. Knottnerus,et al. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. , 1996, International journal of epidemiology.
[39] T. Bowker,et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). , 1996, Heart.
[40] A. Colombo,et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.
[41] B. Gage,et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, Journal of the American Medical Association (JAMA).
[42] G. Albers,et al. Atrial fibrillation and stroke. Three new studies, three remaining questions. , 1994, Archives of internal medicine.
[43] P. Touboul,et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease , 1994, The Lancet.
[44] Stroke Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.
[45] Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy , 1994, BMJ.
[46] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[47] D. Waters,et al. Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina , 1993, Circulation.
[48] P. Roderick,et al. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. , 1993, British journal of clinical pharmacology.
[49] J. Slattery,et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project) , 1992, BMJ.
[50] G. Clagett,et al. Antithrombotic therapy in peripheral arterial occlusive disease. , 1992, Chest.
[51] F. Ferris. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992, JAMA.
[52] D. Stevenson,et al. Aspirin sensitivity. A distressing reaction that is now often treatable. , 1991, Postgraduate medicine.
[53] M. Laakso,et al. The European Stroke Prevention Study , 1991, Neurology.
[54] V. Gebski,et al. Immediate Postoperative Aspirin Improves Vein Graft Patency Early and Late After Coronary Artery Bypass Graft Surgery: A Placebo‐Controlled, Randomized Study , 1991, Circulation.
[55] C. Madden. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .
[56] L. Wilkins. European Stroke Prevention Study. ESPS Group. , 1990, Stroke.
[57] G. FitzGerald. Ticlopidine in unstable angina. A more expensive aspirin? , 1990, Circulation.
[58] D. Bergqvist,et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study , 1990, Journal of internal medicine.
[59] J. Copeland,et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. , 1989, Circulation.
[60] P. Elwood,et al. EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART) , 1989, The Lancet.
[61] H. Adams,et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.
[62] V. Hachinski,et al. THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE , 1989, The Lancet.
[63] P. Théroux,et al. Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.
[64] J. Boissel,et al. Multicenter Double-Blind Study of Ticlopidine in the Treatment of Intermittent Claudication and the Prevention of its Complications , 1988, Angiology.
[65] L Schwartz,et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.
[66] Thomas E. Moritz,et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. , 1988, Circulation.
[67] P. Rigo,et al. Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. , 1987, The Journal of thoracic and cardiovascular surgery.
[68] J. Webster,et al. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts , 1987, The British journal of surgery.
[69] H. Sewell,et al. CYTOCHROME P-450 IMMUNOLOCALISATION IN HUMAN LIVER , 1986, The Lancet.
[70] D. Sackett,et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. , 1985, The New England journal of medicine.
[71] W. Kannel,et al. Update on Some Epidemiologic Features of Intermittent Claudication: The Framingham Study , 1985, Journal of the American Geriatrics Society.
[72] P. Rigo,et al. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. , 1984, The Annals of thoracic surgery.
[73] M. LeWinter,et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.
[74] C. Forbes,et al. RELATION OF ATRIAL FIBRILLATION AND HIGH HAEMATOCRIT TO MORTALITY IN ACUTE STROKE , 1983, The Lancet.
[75] Lippincott Williams Wilkins,et al. Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. , 1980, Circulation.
[76] Persantine and Aspirin in Coronary Heart Disease , 1980 .
[77] J. Mann,et al. Intermittent claudication: prevalence and risk factors. , 1978, British medical journal.
[78] L. Wilhelmsen,et al. SMOKING AND MYOCARDIAL INFARCTION , 1975, The Lancet.
[79] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .
[80] R. Hone,et al. Letter: Methicillin-resistant Staphylococcus aureus. , 1974, Lancet.
[81] S. Marsch,et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. , 2003, Journal of the American College of Cardiology.
[82] E. Ohman,et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. , 2001, Chest.
[83] David R. Wood,et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.
[84] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[85] G. de Gaetano. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. , 2001, Lancet.
[86] J. W. Schaeffer,et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). , 2000, Journal of the American College of Cardiology.
[87] Y. Wang,et al. Ticlopidine-associated aplastic anemia. A case report and review of literature. , 1998, Annals of hematology.
[88] J. Mason,et al. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. , 1998, British medical journal.
[89] Philippe Amouyel,et al. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .
[90] EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. , 1997, European heart journal.
[91] The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. , 1997, Archives of internal medicine.
[92] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[93] A. Schafer. Antiplatelet therapy. , 1996, The American journal of medicine.
[94] 4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. , 1995, Chest.
[95] M. Kindermans,et al. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. , 1994, Nouvelle revue francaise d'hematologie.
[96] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[97] H. White,et al. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .
[99] Thomas E. Moritz,et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. , 1990, Journal of the American College of Cardiology.
[100] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[101] W. Schweizer,et al. The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. , 1979, Journal of chronic diseases.